<DOC>
	<DOCNO>NCT00702364</DOCNO>
	<brief_summary>Atomoxetine medication currently approve FDA treatment attention deficit hyperactivity disorder adult . It gain recent interest alternative medication treat attentional problem relate traumatic brain injury ( TBI ) , 's effectiveness population study . There number advantage Atomoxetine traditional neuro-stimulant medication currently use attentional disorder traumatic brain injury . This study use randomize double-blind placebo-controlled crossover design investigate efficacy atomoxetine improve attention , behavioral function , depression adult TBI</brief_summary>
	<brief_title>Efficacy Study Strattera Treating Attention Disorders Traumatic Brain Injury ( TBI )</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>History TBI Moderate severe TBI indicate Glasgow Coma Score ( GCS ) score 12 less ; Post Traumatic Amnesia ( PTA ) seven day least one year post injury age 1865 ( inclusive ) symptom consistent attentional dysfunction consent participate study history condition would prohibit standard neuropsychological test nonEnglish speaking ( extent would limit ability complete study measure ) prior history significant psychiatric illness require hospitalization epilepsy cardiovascular disease risk include : dysrhythmias , angina , myocardial infarction , uncontrolled hypertension , valvular heart disease include mitral valve prolapse use monoamine oxidase inhibitor drug affect brain monoamine concentration severe renal hepatic impairment pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Attention</keyword>
	<keyword>Traumatic Brain INjury</keyword>
	<keyword>Atomoxetine</keyword>
	<keyword>Strattera</keyword>
</DOC>